Collegium Pharmaceutical (COLL) Consolidated Net Income (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Consolidated Net Income of $14.5 million for Q1 2026, up 499.75% year-over-year from $2.4 million in Q1 2025, and down 14.54% quarter-over-quarter from $17.0 million in Q4 2025.
Collegium Pharmaceutical (COLL) Consolidated Net Income (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Consolidated Net Income history runs 13 years deep, the most recent figure standing at $14.5 million for Q1 2026.
- In Q1 2026, Consolidated Net Income rose 499.75% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $74.9 million (up 70.75% YoY), while the FY2025 annual figure was $62.9 million, down 9.13% from the prior year.
- Consolidated Net Income for Q1 2026 stood at $14.5 million, down from $17.0 million in the prior quarter.
- The five-year high for Consolidated Net Income was $31.9 million in Q4 2023, with the low at -$17.4 million in Q1 2023.
- The 5-year median for Consolidated Net Income is $12.5 million (2024), against an average of $10.0 million.
- The sharpest annual moves came in 2022 and 2023: Consolidated Net Income plunged 183.44% in 2022, then soared 4415.1% in 2023.
- Collegium Pharmaceutical's Consolidated Net Income stood at -$7.2 million in 2022, then surged by 543.67% to $31.9 million in 2023, then slumped by 60.75% to $12.5 million in 2024, then jumped by 35.31% to $17.0 million in 2025, then dropped by 14.54% to $14.5 million in 2026.
- Business Quant data shows COLL's Consolidated Net Income at $14.5 million in Q1 2026, $17.0 million in Q4 2025, and $31.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Collegium Pharmaceutical | 888.13 Mn | 738.81 Mn | 110.29 Mn | -15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.05 Mn |
| Mar 31, 2026 | 14.50 Mn |
| Dec 31, 2025 | 16.96 Mn |
| Sep 30, 2025 | 31.51 Mn |
| Jun 30, 2025 | 11.98 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 12.54 Mn |
| Sep 30, 2024 | 9.34 Mn |
| Jun 30, 2024 | 19.61 Mn |
| Mar 31, 2024 | 27.71 Mn |
| Dec 31, 2023 | 31.94 Mn |
| Sep 30, 2023 | 20.63 Mn |
| Jun 30, 2023 | 13.01 Mn |
| Mar 31, 2023 | -17.43 Mn |
| Dec 31, 2022 | -7.20 Mn |
| Sep 30, 2022 | 457,000.00 |
| Jun 30, 2022 | -5.19 Mn |
| Mar 31, 2022 | -13.07 Mn |
| Dec 31, 2021 | -25.03 Mn |
| Sep 30, 2021 | 8.05 Mn |